SOLID resumes DMD gene therapy trial

Published Date
Sofia Nnorom
Orange box stating: Breaking news research

The U.S. Food and Drug Administration (FDA) has announced that Solid Biosciences can continue its Duchenne trial, IGNITE DMD. The FDA paused the trial after the first participant had a reaction to the gene therapy. Solid has now added extra measures to minimise any safety concerns and is able to continue with recruitment.

Solid expects to report initial results from the trial in the second half of 2019.

For more information please read Solid’s press release and community letter.

For further details about this news story, please contact the MDUK Research Line on 020 7803 4813 or email

Keep in touch